The following article from Practice Update discusses the JAVELIN Renal 101 clinical trial, which compares avelumab plus axitinib versus sunitinib as first-line treatment for advanced renal cell carcinoma (RCC). The article highlights the results of this particular trial and touches upon other combinations of vascular endothelial growth factor (VEGF) inhibitors with immunotherapy as having not just additive, but synergistic, effects for the treatment of advanced RCC. For example, VEGF inhibitors are thought to have some immune-related properties, such as increasing the movement of immune cells into tumours and decreasing the activity of immune suppressor cells allowing the immune system to be stimulated.

Read the full article in Practice Update here